Double attack on blood cancer: stem cell transplant plus CAR-T shows promise
NCT ID NCT07236151
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new approach for adults with a tough-to-treat type of blood cancer called large B-cell lymphoma that had returned or not responded to prior treatment. Participants first received a stem cell transplant using their own cells, followed by infusions of two types of engineered immune cells (CAR-T cells) targeting CD19 and CD22. The goal was to see if this combination could improve the number of patients whose cancer completely disappeared, while monitoring side effects. The trial involved 23 participants and has been completed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTO STEM CELL TRANSPLANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time infusion of Dual-Target CAR-T cells outsmart resistant blood cancers?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a single shot build a cancer army inside the body?
- CAR-T breakthroughs come with infection risks – new study aims to decode them